Russian pharmaceutical company Petrovax on Thursday said 92.5 percent of Russian volunteers in trials of the Chinese Ad5-nCoV vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.

Ad5-nCoV was developed by Chinese company CanSino Biologics in alliance with the Chinese military's research arm.